Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,76 USD | -1,12% | -5,88% | -88,04% |
11/04 | AMYLYX PHARMACEUTICALS, INC. : Baird is Neutraal gestemd over aandeel | ZM |
10/04 | Transcript : Amylyx Pharmaceuticals, Inc. - Special Call |
Vakgebied
Aantal werknemers: 384
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Relyvrio (Sodium Phenylbutyrate and Taurursodiol)
100,0
%
| 22 | 100,0 % | 381 | 100,0 % | +1.612,94% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 22 | 100,0 % | 381 | 100,0 % | +1.612,94% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Justin Klee
FOU | Founder | 34 | 01-01-13 |
Josh Cohen
FOU | Founder | 33 | 01-01-13 |
Jim Frates
DFI | Director of Finance/CFO | 56 | 01-01-21 |
Chief Tech/Sci/R&D Officer | 71 | 28/11 | |
Lindsey Allen
IRC | Investor Relations Contact | - | - |
Gina Mazzariello
LAW | General Counsel | 53 | 23-02-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
George Milne
CHM | Chairman | 80 | 01-01-15 |
Kari Firestone
BRD | Director/Board Member | - | 16-03-23 |
Paul R. Fonteyne
BRD | Director/Board Member | 63 | 29-03-21 |
Daphne Quimi
BRD | Director/Board Member | 58 | 29-06-21 |
Josh Cohen
FOU | Founder | 33 | 01-01-13 |
Justin Klee
FOU | Founder | 34 | 01-01-13 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 67 782 139 | 55 854 779 ( 82,40 %) | 0 | 82,40 % |
Bedrijfsgegevens
Sector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-88,04% | 120 mln. | |
-4,66% | 86,13 mld. | |
+1,32% | 39,82 mld. | |
-19,27% | 30,42 mld. | |
+57,86% | 25,23 mld. | |
-16,09% | 15,36 mld. | |
-9,14% | 11,95 mld. | |
-17,69% | 11,6 mld. | |
-43,00% | 11,51 mld. | |
+5,24% | 8,71 mld. |
- Beurs
- Aandelen
- Koers AMLX
- Onderneming Amylyx Pharmaceuticals, Inc.